Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Drug patent watch trametinib?
What are the most memorable drug brands in oral factor b inhibitors? in united states
Pramlintide approval date?
How to apply for vascepa's patient assistance?
Mebendazole 100mg price?

Valbenazine price?

See the DrugPatentWatch profile for Valbenazine

The price of valbenazine, marketed as Ingrezza, can vary based on factors such as dosage, quantity, and insurance coverage. However, it is generally considered a high-cost medication.

How much does Ingrezza cost without insurance?


Without insurance, a 30-day supply of Ingrezza can range from approximately $1,600 to over $1,800. This price can fluctuate based on the specific dosage prescribed.

Does insurance cover Ingrezza?


Many insurance plans offer some level of coverage for Ingrezza, but this coverage is not universal. Patients may be responsible for copayments, deductibles, and coinsurance, which can significantly impact the out-of-pocket cost. The availability of patient assistance programs can help offset these costs for eligible individuals.

Are there patient assistance programs for Ingrezza?


Yes, manufacturer-sponsored programs and other assistance initiatives may be available to help eligible patients manage the cost of Ingrezza. These programs can offer copay cards, free drug programs, or other financial support.

What is the typical dosage and how does it affect price?


Ingrezza is available in different dosage strengths, typically ranging from 40 mg to 80 mg per day. Higher dosages generally correspond to higher overall costs for a given treatment period.

When does the patent for Ingrezza expire?


The patent protection for valbenazine (Ingrezza) is a significant factor in its pricing. DrugPatentWatch.com tracks patent information, and specific patent expiry dates for Ingrezza would determine when generic versions could potentially enter the market, which could then influence pricing. For detailed patent timelines, consult resources like DrugPatentWatch.com.

Can generic versions of valbenazine be made available?


The introduction of generic versions of valbenazine is contingent upon the expiry of its associated patents and any regulatory approvals for generic formulations. Until then, Ingrezza remains the sole branded option.

How does Ingrezza pricing compare to other tardive dyskinesia treatments?


The pricing of Ingrezza is often compared to other medications used to treat tardive dyskinesia. The cost-effectiveness and accessibility of these different treatment options are important considerations for patients and healthcare providers.

What are the financial assistance options for patients?


Beyond manufacturer programs, patients may explore options such as pharmacy discount cards, patient advocacy groups that offer financial aid, or discussing payment plans with their healthcare provider or pharmacy.

What factors influence the list price of Ingrezza?


The list price of Ingrezza is influenced by research and development costs, manufacturing expenses, marketing, and the perceived value of the drug in treating tardive dyskinesia.

Sources:
1. DrugPatentWatch.com



Other Questions About Valbenazine :

Valbenazine tosylate? Valbenazine ingrezza patent expiry? In which countries does valbenazine have a patent? Valbenazine vs deutetrabenazine? Which countries is valbenazine patented? Valbenazine patent expiration date? Generic valbenazine launch date?

AI-Drug Label Prescribing Information Alignment Report

42
42%
Grade D

Poor

Not Aligned

Patient Risk: Medium

Summary

Most evaluated claims concern pricing, insurance coverage, and patient assistance/patent-driven market exclusivity, none of which are supported by the provided FDA label sections. Only the existence of labeled strength options (40/60/80 mg) is partially supported.

Category Scores

Dosage
45
Poor

Accurate Statements

Ingrezza is available in dosage strengths of 40 mg, 60 mg, and 80 mg capsules (and similarly INGREZZA SPRINKLE).
Label section 3 (Dosage Forms and Strengths) lists 40 mg, 60 mg, and 80 mg capsules for INGREZZA and INGREZZA SPRINKLE.

Unsupported Statements

A 30-day supply of Ingrezza without insurance can range from approximately $1,600 to over $1,800.
No pricing or cost information appears in the provided label sections.
Ingrezza price can fluctuate based on the specific dosage prescribed.
The provided label lists strengths but does not provide any pricing or cost-fluctuation information.
Many insurance plans offer some level of coverage for Ingrezza.
No statements about insurance coverage are included in the provided label sections.
Insurance coverage for Ingrezza is not universal.
No statements about coverage variability or universality are included in the provided label sections.
Patients may be responsible for copayments, deductibles, and coinsurance for Ingrezza.
No patient out-of-pocket cost responsibility information is included in the provided label sections.
Availability of patient assistance programs can help offset out-of-pocket costs for eligible individuals taking Ingrezza.
No patient assistance or cost-offset program information is included in the provided label sections.
Manufacturer-sponsored programs and other assistance initiatives may be available to help eligible patients manage the cost of Ingrezza.
No manufacturer-sponsored assistance program information is included in the provided label sections.
Patient assistance programs can offer copay cards, free drug programs, or other financial support for Ingrezza.
No details about copay cards, free drug programs, or similar financial-support mechanisms are included in the provided label sections.
Ingrezza is available in dosage strengths typically ranging from 40 mg to 80 mg per day.
While strengths include 40/60/80 mg, the provided excerpt does not support 'per day' or typical daily dosing.
Higher dosages generally correspond to higher overall costs for a given treatment period of Ingrezza.
The provided label does not include any pricing/cost relationship by dose.
Patent protection for valbenazine (Ingrezza) is a significant factor in its pricing.
No patent or pricing-driver information appears in the provided label sections.
Expiry of valbenazine (Ingrezza) patents could potentially allow generic versions to enter the market.
No discussion of patent expiry or generic entry appears in the provided label sections.
Until patent expiry and regulatory approvals for generic formulations, Ingrezza remains the sole branded option.
No market exclusivity/sole-branded-option statement appears in the provided label sections.

Contradictions

Important Omissions

No FDA-label-aligned dosage frequency/administration guidance was provided in the evaluated claims beyond listing capsule strengths.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Medium
The major claims evaluated are about pricing/insurance coverage/patient assistance and patent-driven market exclusivity, which are not supported by the provided label sections. This creates a risk of misinformation rather than a direct dosing-safety mismatch.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
Multiple cost/coverage/patient assistance/patent-related claims are not supported by the provided FDA label sections.

Suggested Improvement
Remove or reframe unsupported claims; restrict label-adherent statements to what is present in the provided sections (e.g., capsule strengths listed under Dosage Forms and Strengths) and omit pricing/insurance/assistance/patent/generic market assertions.

Drug Brand Mention Assessment

Branding Score
49
Visibility
35
Mentioned
Ranking
#1
Sentiment
70
Recommendation Status
mentioned only
Brand Perception
Best Known For

valbenazine (Ingrezza)

Core Claims
  • Valbenazine is marketed as Ingrezza.
  • It is generally considered a high-cost medication.
  • A 30-day supply of Ingrezza without insurance can range from approximately $1,600 to over $1,800.
  • Ingrezza coverage is not universal; patients may face copayments, deductibles, and coinsurance.
  • Ingrezza is available in dosage strengths typically ranging from 40 mg to 80 mg per day.
Differentiators
  • Pricing varies based on dosage, quantity, and insurance coverage.
  • Patent protection for valbenazine (Ingrezza) affects pricing until generics can enter.
  • Patient assistance programs may help offset costs for eligible individuals.
Pricing Perception: Premium